Comparative Pharmacology
Head-to-head clinical analysis: DARUNAVIR ETHANOLATE versus LEXIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARUNAVIR ETHANOLATE versus LEXIVA.
DARUNAVIR ETHANOLATE vs LEXIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits the cleavage of HIV-encoded Gag-Pol polyproteins in infected cells, thereby preventing the formation of mature infectious virus particles.
Fosamprenavir is a prodrug of amprenavir, a protease inhibitor (PI) that competitively inhibits HIV-1 protease, preventing cleavage of viral Gag-Pol polyprotein, resulting in immature, non-infectious viral particles.
600 mg orally twice daily with ritonavir 100 mg twice daily, or 800 mg orally once daily with ritonavir 100 mg once daily and with food.
1400 mg orally twice daily (with ritonavir 100 mg) or 1400 mg orally once daily (with ritonavir 100 mg and cobicistat 150 mg). For treatment-naïve patients, 1400 mg orally once daily with ritonavir 100 mg or cobicistat 150 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours when coadministered with ritonavir (100 mg), and about 5-6 hours without booster. Clinical context: allows once-daily or twice-daily dosing with boosting.
Terminal elimination half-life is 2.8 to 5.7 hours; with ritonavir boosting, half-life increases to 7-10 hours, allowing once-daily dosing.
Primarily hepatic metabolism via CYP3A4, followed by biliary excretion of metabolites; renal excretion of unchanged drug is minimal (<10%). In feces, approximately 79% of dose is recovered as metabolites; in urine, <10% as unchanged drug.
Renal (approximately 82% in urine, with 14% as parent drug and 68% as metabolites); fecal (approximately 16%, with 7% as parent drug).
Category A/B
Category C
Protease Inhibitor
Protease Inhibitor